Imfinzi-Imjudo dual immunotherapy offers new option for 1st-line treatment of liver cancer < Pharma < Article
As AstraZeneca launches Imjudo (tremelimumab) without health insurance coverage in May, Korean liver cancer patients will likely have...
As AstraZeneca launches Imjudo (tremelimumab) without health insurance coverage in May, Korean liver cancer patients will likely have...